Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

The Ebolavirus Infections pipeline market report provides a comprehensive overview on the therapeutics under development for Ebolavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections and features dormant and discontinued projects.

Key Targets in the Ebolavirus Infections Pipeline Drugs Market

In the Ebolavirus Infections pipeline drugs market the key targets are Glycoprotein, RNA Directed RNA Polymerase, Cell Membrane, Ebola virus Matrix Protein VP40, Niemann Pick C1 Protein, RNA, 70 kDa Ribosomal Protein S6 Kinase, Cathepsin B, Cathepsin L1, and Cells Expressing Phosphatidylserine.

Ebolavirus Infections Pipeline Drugs Market, by Targets

Ebolavirus Infections Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Types of Key MoA in the Ebolavirus Infections Pipeline Drugs Market

Glycoprotein Inhibitor has the highest number of pipeline products followed by RNA Directed RNA Polymerase Inhibitor, Cell Membrane Disruptor, Niemann Pick C1 Protein Inhibitor, RNA Synthesis Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cathepsin B Inhibitor, Cathepsin L1 Inhibitor, Cytotoxic To Cells Expressing Phosphatidylserine, and Ebola virus Matrix Protein VP40 Inhibitor.

Ebolavirus Infections Pipeline Drugs Market, by MoA

Ebolavirus Infections Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Ebolavirus Infections Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Ebolavirus Infections pipeline drugs market are intramuscular, intravenous, oral, inhalational, nasal, parenteral, subcutaneous, topical, intradermal, and sublingual. Intramuscular has the maximum number of pipeline products.

Ebolavirus Infections Pipeline Drugs Market Analysis, by RoA

Ebolavirus Infections Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Ebolavirus Infections Pipeline Drugs Market

The key molecule types in the Ebolavirus Infections pipeline drugs market are small molecule, monoclonal antibody, recombinant vector vaccine, subunit vaccine, antibody, vaccine, DNA vaccine, protein, antisense oligonucleotide, and gene therapy.

Ebolavirus Infections Pipeline Drugs Market, by Molecule Type

Ebolavirus Infections Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Ebolavirus Infections Pipeline Drugs Market

The major companies in the Ebolavirus Infections pipeline drugs market Mapp Biopharmaceutical Inc, Integrated BioTherapeutics Inc, Collaborations Pharmaceuticals Inc, Emergent BioSolutions Inc, Galactica Biotech Ltd, TFF Pharmaceuticals Inc, AIkido Pharma Inc, ANP Technologies Inc, BioComo Inc, and Celdara Medical LLC.

Ebolavirus Infections Pipeline Drugs Market, by Major Companies

Ebolavirus Infections Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Ebolavirus Infections Pipeline Drugs Market Overview

Key Targets Glycoprotein, RNA Directed RNA Polymerase, Cell Membrane, Ebola virus Matrix Protein VP40, Niemann Pick C1 Protein, RNA, 70 kDa Ribosomal Protein S6 Kinase, Cathepsin B, Cathepsin L1, and Cells Expressing Phosphatidylserine
Key Mechanisms of action Glycoprotein Inhibitor, RNA Directed RNA Polymerase Inhibitor, Cell Membrane Disruptor, Niemann Pick C1 Protein Inhibitor, RNA Synthesis Inhibitor, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cathepsin B Inhibitor, Cathepsin L1 Inhibitor, Cytotoxic To Cells Expressing Phosphatidylserine, and Ebola virus Matrix Protein VP40 Inhibitor
Key Routes of Administration Intramuscular, Intravenous, Oral, Inhalational, Nasal, Parenteral, Subcutaneous, Topical, Intradermal, and Sublingual
Key Molecule Types Small Molecule, Monoclonal Antibody, Recombinant Vector Vaccine, Subunit Vaccine, Antibody, Vaccine, DNA Vaccine, Protein, Antisense Oligonucleotide, and Gene Therapy
Major Companies Mapp Biopharmaceutical Inc, Integrated BioTherapeutics Inc, Collaborations Pharmaceuticals Inc, Emergent BioSolutions Inc, Galactica Biotech Ltd, TFF Pharmaceuticals Inc, AIkido Pharma Inc, ANP Technologies Inc, BioComo Inc, and Celdara Medical LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections
  • The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ebolavirus Infections therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ebolavirus Infections therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Ebola Hemorrhagic Fever

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ebola Hemorrhagic Fever
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abivax SA
AIkido Pharma Inc
AlphaVax Inc
AnGes Inc
ANP Technologies Inc
AntoXa Corp
Arisan Therapeutics Inc
Auro Vaccines LLC
Bharat Biotech Ltd
BioComo Inc
BioCryst Pharmaceuticals Inc
BioFactura Inc
Biotron Ltd
Celdara Medical LLC
Chicago Biosolutions Inc
Cocrystal Pharma Inc
Collaborations Pharmaceuticals Inc
Emergent BioSolutions Inc
Emergex Vaccines Holding Ltd
Fab’entech SA
Fibroplate Inc
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc
Galactica Biotech Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
GeoVax Labs Inc
Gilead Sciences Inc
Global BioLife Inc Ltd
Greffex Inc
H&P Labs Inc
ImmunityBio Inc
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
IntelliStem Technologies Inc
Johnson & Johnson
Mapp Biopharmaceutical Inc
Merck & Co Inc
Microbiotix Inc
Micropharm Ltd
Novavax Inc
Nykode Therapeutics AS
Oita University Institute of Advanced Medicine Inc
OncXerna Therapeutics Inc
Orgenesis Inc
Ostrich Pharma USA Inc
Palisades Therapeutics
PanThera Biopharma LLC
Phelix Therapeutics LLC
Phoenix Biotechnology Inc
Public Health Vaccines LLC
Regeneron Pharmaceuticals Inc
ReVacc Biotech
Riboscience LLC
Rodos BioTarget GmbH
SAB Biotherapeutics Inc
Secarna Pharmaceuticals GmbH & Co KG
Selva Therapeutics Inc
Sihuan Pharmaceutical Holdings Group Ltd
Soligenix Inc
TFF Pharmaceuticals Inc
Tiba Biotech LLC
Tonix Pharmaceuticals Holding Corp
Uvax Bio LLC
Vaxeal Holding SA
Vir Biotechnology Inc
XBiotech Inc
Xenothera SAS
Yaso Therapeutics Inc
Yisheng Biopharma Co Ltd
Zalgen Labs LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Overview

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Companies Involved in Therapeutics Development

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drug Profiles

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2022

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Ebolavirus Infections (Ebola Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.